###### Strengths and limitations of this study

-   The study examines the impact of ambulatory care sensitive conditions (ACSCs) on the acute publicly funded hospital system using national level data extracted from the national Hospital In-patient Enquiry System in the form of bed days and bed day rates.

-   National bed day rates are standardised to the European Union population with three age-specific cohorts analysed (children 0--15, adults 15--64 and persons 65 and older) as well as trend analysis over the 5-year period 2011--2016 using Poisson regression techniques.

-   All 19 ACSCs identified are included in the prioritisation exercise which identifies the top five contributors to ACSC bed days for the total population as well as for each age cohort examined.

-   While the current analysis of capacity and age cohorts remains robust, further in-depth analysis of patient profiles was limited by the episodic nature of Irish National Hospital In-patient Enquiry System data, where admissions are not linked to patient details.

-   The generalisability of all ACSC research is limited by poorly defined categorisation of ACSCs internationally, and a refinement of coding would enhance specificity and generalisability of this area of research.

Introduction {#s1}
============

Ambulatory care sensitive conditions (ACSCs) are acute or episodic conditions where appropriate and timely community care can prevent disease and/or hospital admissions.[@R1] While there is variability in relation to the conditions considered ACSCs, they can be broadly classified into vaccine preventable, acute and chronic conditions. ACSCs are commonly used as an indicator of avoidable hospital admissions as well as quality of and access to primary care.[@R2]

The current Irish acute hospital bed occupancy rate of 94.2% is significantly higher than the internationally recognised target of 85%. Occupancy rates at this level are associated with adverse patient and staff outcomes as well as restricting efficiency in terms of patient flow.[@R4] To achieve international standards of bed occupancy would require the immediate introduction of 1 260 inpatient beds.[@R5] Ireland is experiencing an ageing demographic shift with an expected annual increase of almost 20 000 in the population 65 years and over. This population cohort currently occupy 54% of total acute bed days.[@R6] Moreover, the demand for acute hospital beds is projected to increase significantly unless there is a shift in the model of care from acute hospital care to primary care.[@R6] The hospital centric nature of the Irish system continues to fuel an ever increasing demand for acute hospitals to deliver care and services which would be better provided in the community. However, primary care services in Ireland remain under resourced.[@R7] As recognised within Slaintecare, the 10-year cross political vision for the future of Irish healthcare services, improvement and sustainability of the Irish Health system is dependent on a shift of care from acute hospitals to primary care.[@R7]

In the literature, ACSC analyses to date recognises the impact on emergency departments and admissions. Drivers of these admissions have been examined highlighting the association with levels of primary care provision, as well as higher levels of deprivation.[@R1] However, the use of ACSC analysis to identify and prioritise areas for improved primary care resources and programmes of care remains unexamined. The purpose of this paper is to examine ACSCs in relation to their overall impact on acute hospital capacity in Ireland in terms of bed days and bed day rates and to assist prioritisation of targeted investment in primary care supporting robust integrated care programmes. This novel approach to the evaluation of ACSCs supports the left shift to primary care called for by Slaintecare and international policy.

Methods {#s2}
=======

The international literature in relation to 'definition and coding' of ACSCs was reviewed and a list of 19 commonly cited ACSCs was identified for inclusion ([online supplementary appendix 1](#SP1){ref-type="supplementary-material"}). Definition notes for International Classification of Disease (ICD) codes including primary and secondary diagnoses were examined and the definition notes most appropriate to the Irish setting and reflective of bed utilisation were chosen. Data for these codes was extracted from the National Hospital In-patient Enquiry System to calculate 2011--2016 age-standardised bed day rates for selected ACSC conditions. Age specific analysis was carried out using the following categories; children (0--14 years), adults (15--64 years) and persons 65 years and over. A prioritisation exercise in which all 19 conditions were ranked in terms of their contribution to total and age specific bed days and bed day rates in 2017 was undertaken to identify the most significant contributors within our hospital system ([figure 1](#F1){ref-type="fig"}). Poisson regression analysis was used to distinguish a genuine change over time. Standardised incidence rate ratios (IRR) with 95% CIs and corresponding p values were reported.[@R10] Population rates are directly standardised to the European standard population.
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![Impact of ACSCs on bed days in public acute hospitals in Ireland in 2016 by age cohort. ACSC, ambulatory care sensitive condition; COPD, chronic obstructive pulmonary disease.](bmjopen-2018-028744f01){#F1}

Patient and public involvement {#s2-1}
------------------------------

Patients were not involved in the concept or design of this study.

Results {#s3}
=======

ACSCs represented 18.5% (n=871 328) of publicly funded bed days in Ireland in 2016 with an 18.2% (IRR 1.03; p\<0.01) increase over the 5-year time period examined. The most significant contributors to ACSC bed days included influenza and pneumonia, chronic obstructive pulmonary disease (COPD) and pyelonephritis. Influenza and pneumonia accounted for 39.0% of total ACSC bed days (n=339 613), with the proportion of ACSC bed days increasing with increasing age across the three age cohorts examined ([table 1](#T1){ref-type="table"}; [figure 1](#F1){ref-type="fig"}). The bed day rate increased by 8.2% (IRR 1.02; p\<0.01) from 2011 to 2016 ([table 2](#T2){ref-type="table"}). COPD accounted for almost half of chronic ACSC bed days in 2016 and 14.5% of total ACSC bed days (n=126 336 bed days; 3831/100 000). The COPD bed day rate increased (2011--2016) by 1.1% (IRR:1.16; p\<0.01) on a background of a 10.7% reduction in the chronic ACSC bed day rate over the 5-year period examined.

###### 

ACSC contribution to national bed days by age cohort in 2016

  ACSCs                                                    Total                   0--14      15--64       65+                                                                                     
  -------------------------------------------------------- ------------- --------- ---------- ------------ ------------ ------ ---------- ------------- ------ ---------- ------------- ---------- ------------
  Vaccine preventable                                      340 461       39.1      7.2        10 170       11 276       24.1   11 141     80 775        36.4   2826       248 545       41.3       41 933
   Influenza and pneumonia                                 339 613       39.0      7.2        10 155       10 704       22.9   930        80 518        36.2   2817       248 524       41.3       41 930
   Other vaccine preventable                               848           0.1       0.0        14           572          1.2    76         257           0.1    81         21            0.0        3
  Acute                                                    252 698       29.0      5.4        7002         29 822       63.7   2809       73 371        32.8   2471       150 172       24.9       25 431
   Pyelonephritis                                          120 285       13.8      2.6        3681         6282         13.4   547        19 762        8.9    680        94 338        15.7       16 145
   Cellulitis                                              46 088        5.3       1.0        1307         2512         5.4    182        15 403        6.9    5334       28 141        4.7        4734
   Convulsions and epilepsy                                36 161        4.2       0.8        857          7026         15.0   707        17 426        7.7    5725       11 993        2.0        1967
   Dehydration and Gastro Intestinal Infection             7594          0.9       0.2        216          149          0.3    27         2713          1.2    911        4740          0.8        794
   Dental                                                  8422          1.0       0.2        162          4308         9.2    466        3374          1.5    110        809           0.1        126
   Ear Nose & Throat infections                            15 443        1.8       0.3        282          9090         19.4   881        5401          2.3    1675       1171          0.2        193
   Gangrene                                                11 372        1.3       0.2        308          417          0.9    80         5128          2.3    1780       5827          1.0        956
   Perforated ulcer                                        5575          0.6       0.1        153          10           0.0    29         2597          1.2    896        2969          0.5        487
   Pelvic Inflammatory Disease                             1758          0.2       0.0        37           28           0.1    1          1567          0.7    485        184           0.0        29
  Chronic                                                  278 169       31.9      5.9        8227         5704         12.2   562        68 790        30.9   2448       203 675       **33.8**   33 631
   COPD                                                    126 336       14.5      2.7        3831         140          0.3    23         23 500        10.6   5928       102 659       17.0       16 749
   Congestive Heart Failure                                68 469        7.3       1.5        2059         141          0.3    22         6425          3.0    2478       61 904        9.4        9735
   Diabetic complications                                  40 241        4.6       0.9        1081         1656         3.5    142        17 259        7.7    5928       21 479        3.6        3457
   Angina                                                  15 179        1.7       0.3        430          13           0.0    1          5780          2.6    2125       9386          1.6        1499
   Asthma                                                  14 519        1.7       0.3        318          3703         7.9    327        7889          3.5    2639       3015          0.5        471
   Hypertension                                            5586          0.6       0.1        144          177          0.4    10         3158          1.4    1076       2268          0.4        371
   Iron deficiency anaemia                                 12 523        1.4       0.3        357          180          0.4    21         4449          2.0    1514       7915          1.3        1318
   Nutritional deficiencies                                225           0         0.0        7            5            0.0    0          42            0.0    13         178           0.0        31
  **ACSC contribution to total bed days in each cohort**   **871 328**   **100**   **18.5**   **18 297**   **46 802**          **4650**   **222 936**          **7113**   **602 392**              **94 483**

\*Rates are standardised to the European standard population

ACSC, ambulatory care sensitive condition; COPD, chronic obstructive pulmonary disease.

###### 

Trend analysis of ACSC bed days in Irish acute public hospitals 2011--2016

  ACSC                                           Absolute change in bed days   \% change in standardised bed day rate   Incidence rate ratio for trend   95% CI
  ---------------------------------------------- ----------------------------- ---------------------------------------- -------------------------------- ----------------------------
  Vaccine preventable                                                                                                                                    
   **Total**                                     **62 395**                    **8.2**                                  **1.02\*\*\***                   **1.017 to** **1.027**
   Influenza and pneumonia                       62 700                        8.2                                      1.02\*\*\*                       1.018 to 1.027
   Other vaccine preventable                     −305                          −25.4                                    0.90\*                           0.791 to 1.014
  Acute                                                                                                                                                  
   **Total**                                     **56 773**                    **19.7**                                 **1.03\*\*\***                   **1.028 to** **1.040**
   Pyelonephritis                                46 554                        46.5                                     1.07\*\*\*                       1.064 to 1.083
   Cellulitis                                    13 284                        21.5                                     1.05\*\*\*                       1.035 to 1.063
   Convulsions and epilepsy                      3829                          5.1                                      1.01                             0.9905 to 1.023
   Dehydration and Gastro Intestinal Infection   −4,405                        −44.9                                    0.94\*\*\*                       0.913 to 0.967
   Dental                                        393                           3.7                                      1.00                             0.963 to 1.036
   Ear Nose & Throat infections                  250                           5.5                                      1.00                             0.973 to 1.029
   Gangrene                                      −538                          −22.1                                    0.98                             0.955 to 1.010
   Perforated ulcer                              −2,280                        −38.2                                    0.93\*\*\*                       0.898 to 0.967
   Pelvic Inflammatory Disease                   −314                          −22.5                                    0.96                             0.893 to 1.038
  Chronic                                                                                                                                                
   **Total**                                     −**7,442**                    −**10.7**                                **0.97\*\*\***                   **0.969 to** **0.979**
   COPD                                          18 107                        1.1                                      1.16\*\*\*                       1.157 to 1.171
   Congestive Heart Failure                      −1,201                        −11.4                                    0.97\*\*\*                       0.961 to 0.980
   Diabetic complications                        −11,444                       −34.1                                    0.91\*\*\*                       0.902 to 0.924
   Angina                                        −8,163                        −43.8                                    0.90\*\*\*                       0.885 to 0.9195
   Asthma                                        2877                          17.6                                     1.03\*\*                         1.007 to 1.063
   Hypertension                                  774                           3.0                                      1.01                             0.967 to 1.047
   Iron deficiency anaemia                       3916                          40.5                                     1.05\*\*\*                       1.026 to 1.083
   Nutritional deficiencies                      174                           633.7                                    1.08                             0.838 to 1.380
  **ACSC contribution to public bed days**       **111 726**                   **18.2**                                 **1.03\*\*\***                   **1.033** **to** **1.034**

\* p\<0.1; \*\*P\<0.05; \*\*\*p\<0.01

ACSC, ambulatory care sensitive condition; COPD, chronic obstructive pulmonary disease.

Pyelonephritis represented almost half (51.2%; n=120 285 bed days; 3681/100 000) of acute ACSC bed days in 2016 and 13.8% of total ACSC bed days. The bed day rate for pyelonephritis increased by 46.5% over the 5 years examined.

Examination by age cohort {#s3-1}
-------------------------

When age-specific bed day rates were examined significant variation becomes apparent ([figure 2](#F2){ref-type="fig"}). ACSC conditions were concentrated in the older population, with adults 65 and older representing 69.1% of ACSC bed days (n=602 392 bed days; 94 483/100 000) in 2016. The impact of ACSCs on total bed days also increased with age, with ACSC bed days representing a quarter of total bed days in this age cohort. Vaccine preventable conditions represented 41.3% of ACSC bed days among this cohort of which 99% (n=248 524 bed days; 41 933/100 000) were due to influenza and pneumonia. COPD was the most significant chronic ACSC among this age cohort accounting for more than 100 000 bed days (16 749/100 000). In 2016, pyelonephritis was the most significant acute ACSC in this cohort with 94 338 bed days (16 145/100 000). The bed day rate due to pyelonephritis increased by 46.5% over the 5 years examined (IRR 1.07; p\<0.01) ([table 2](#T2){ref-type="table"}).

![Bed day rate by 5-year age bands for top three ACSCs among total population. ACSC, ambulatory care sensitive condition; COPD, chronic obstructive pulmonary disease.](bmjopen-2018-028744f02){#F2}

In the child cohort (0--14 years), 13.8% of total acute hospital bed days were attributable to ACSCs, representing 46 802 bed days in 2016 ([table 2](#T2){ref-type="table"}). Acute ACSCs represented 63.4% (n=29 822 bed days; 2089/100 000), with ENT infections the leading acute condition, representing 19.4% (n=9090 bed days; 881/100 000) of ACSC bed days in 2016. Vaccine preventable ACSCs represented almost a quarter (24.1%) of ACSC bed days, with influenza and pneumonia being responsible for the majority of these.

Within the adult cohort (15--64 years), 11.0% (n=222 936 bed days; 7113/100 000) of total bed days were attributable to ACSCs ([table 1](#T1){ref-type="table"}). The most significant ACSC condition among this age cohort was the vaccine preventable category influenza and pneumonia. Acute and chronic ACSCs contributed similar proportions to bed days at approximately one-third each.

Discussion {#s4}
==========

The 19 ACSCs identified for inclusion in this analysis accounted for almost 20% of the total publicly funded acute hospital bed days in 2016 or 871 328 bed days. When examined in relation to age specific cohorts, adults 65 years and over represented 69.1% of all ACSC bed days. Just over half of ACSC bed days in 2016 were among respiratory conditions; influenza and pneumonia and COPD. Influenza and pneumonia was the single most important contributor to ACSC bed days across all age cohorts, increasing by 8.2% over the 5 years examined. The majority of these bed days (73.2%; n=248 524 bed days) were among adults 65 years and over. COPD represented 14.5% (n=126 336) of ACSC bed days in 2016, with 81.3% of these in adults 65 years and over. Pyelonephritis was the next biggest contributor to bed days, representing 13.8% of ACSC bed days. Again, the relative contribution to bed days increased with age, with adults 65 years and over representing 78.4%. Over the 5-year period examined bed days due to pyelonephritis increased significantly (46.5%).

Evidence-based models of care for influenza and pneumonia include integrated care programmes which include prevention. Seasonal influenza and pneumococcal vaccination remain the mainstay of preventing mortality and morbidity associated with influenza and pneumonia in Ireland and internationally. Seasonal influenza vaccination is recommended for disease specific risk groups including those with COPD, adults 65 years and over and healthcare workers (HCWs). Pneumococcal vaccination is recommended for those 65 and over and those with COPD. While the absolute impact of seasonal influenza and pneumococcal vaccination remains difficult to quantify, recent studies confirm their effectiveness at reducing the risk of pneumococcal pneumonia as well as hospitalisation from respiratory illness among adults 65 and over.[@R11] Despite this, uptake of seasonal influenza vaccine in Ireland consistently lags behind our closest neighbour the UK, while rates of uptake of pneumococcal vaccination are not routinely collected. In Ireland, uptake of seasonal influenza vaccine among adults 65 and over was 56.9% for the 2012/2013 season, with uptake among HCWs at just 17.6%. Pneumococcal vaccine uptake was estimated at 36%.[@R13] Comparatively, in the UK, seasonal influenza vaccination rates consistently approach or exceed 70% among adults over 65, with HCW vaccination rates consistently above Irish estimates ([table 3](#T3){ref-type="table"}).[@R16] For the 2012/2013 season, for which comparative data is available, pneumonia represented approximately 10% of ACSC admissions in the UK compared with approximately 30% in the Irish setting.[@R1] These estimates support the continued emphasis on seasonal influenza and pneumococcal vaccination for HCWs and adults 65 and over, as well as the regular monitoring of pneumococcal vaccination uptake rates in Ireland.

###### 

Comparative vaccination uptake figures 2012/2013 and 2017/2018

            2012/2013   2017/2018                                          
  --------- ----------- ----------- ------- -------------- ------- ------- -------
  Ireland   56.9%       17.6%       38.0%   29.0%--35.0%   68.0%   44.8%   38.0%
  UK        74.0%       45.6%       69.1%   15.0%          70.5%   68.7%   69.5%

ACSC, ambulatory care sensitive condition; HCW, healthcare worker.

Ireland consistently has one of the highest admission and re-admission rates for COPD in the Organization for Economic Co-operation and Development (OECD).[@R18] COPD is also one of the most resource intensive Dagnosis Related Groups in acute hospitals in Ireland.[@R6] Mortality rates in Ireland due to chronic lower respiratory diseases are 42% higher than the EU average.[@R6] Pulmonary rehabilitation is one of the most cost-effective treatments available.[@R20] At a cost of 2,000--8,000 per Quality Adjusted Life Year, it is known to be effective at improving quality of life and reducing hospital admissions. Despite being recognised as the standard of care, this programme is not routinely available in Ireland.[@R21] While COPD patients are identified as a risk group for both influenza and pneumococcal vaccination in Ireland, vaccination uptake among this group is not routinely measured or reported.[@R18] This paper provides evidence to support implementation of an integrated care programme for COPD focusing on primary care investment to reduce pressure on acute hospitals and improve the quality of care for patients delivered closer to home.

The impact and increase observed for pyelonephritis is surprising, though a similar trend has been observed in the UK.[@R10] Further exploration of this phenomenon is necessary in order to ascertain patient profile and appropriateness of admissions. Available evidence demonstrates that with appropriate primary care support in the form of diagnostics, treatment guidelines and preventive approaches, admissions can be reduced and care provided closer to home.[@R22]

Conclusion {#s5}
==========

ACSCs are a high-level indicator of potentially avoidable hospitalisation with admissions known to be correlated with primary care provision as well as with deprivation.[@R1] The impact of ACSCs on acute hospital capacity is best measured using bed day rates. This analysis can be used to identify conditions that would benefit from investment in primary and community care. Identifying specific conditions by their impact on acute hospital capacity supports closer examination of integrated models of care for these conditions.[@R7] This analysis not only supports the left shift to provision of care within the community called for in Slaintecare, but enables prioritisation of resources to primary care.[@R6]

ACSCs were responsible for almost one-fifth of all acute hospital bed day usage in 2016 in Ireland. While the proportion of these admissions that represent truly avoidable admissions will require further exploration, an examination of the impact of these conditions in terms of bed days make a compelling argument for prioritising the development of integrated models of care with primary and community services, enabling the 'left shift' of care closer to home envisioned within government policy.[@R6]
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